East Asian Pharmaceutical Market 2016-2026 : Prospects for Growth Among Drug Classes in Japan, Taiwan and Korea

東アジアの製薬市場:日本、台湾、韓国

◆タイトル:East Asian Pharmaceutical Market 2016-2026 : Prospects for Growth Among Drug Classes in Japan, Taiwan and Korea
◆商品コード:VGAIN6041531
◆調査・発行会社:visiongain
◆発行日:2016年3月
◆ページ数:132
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:アジア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名利用)GBP1,999 ⇒換算¥309,845見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥464,845見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥774,845見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

本調査レポートでは、"東アジアの製薬市場:日本、台湾、韓国"について調査・分析し、レポートサマリー、世界市場規模・市場予測、地域別市場分析、主要国別市場分析、市場環境分析、結論などの情報をお届けいたします。

What can be expected from the East Asian pharmaceutical market? Which areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects there.
Our 132-page report provides 67 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall regional market and national level. You will see financial results, an interview, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2016-2026 and other analyses show you commercial prospects
Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter’s Five Forces analysis) and commercial developments.

See revenue forecasts for the leading submarkets and indications
How will submarkets perform to 2026? Our study forecasts revenues in Japan, Taiwan and Korea for the following drug classes:
• Generic Drugs
• Originator Drugs
• OTC Drugs
• Biosimilars

Leading companies and potential for market growth
Overall revenue for the East Asian pharmaceutical market will reach $121.5bn in 2020, our work forecasts. We predict strong revenue growth through to 2026. The ageing of the population in each country results in strong opportunities for increased pharmaceutical sales.

Our work analyses the key companies in the market. See visiongain’s analysis of 13 leading companies, including these:
• Takeda
• Astellas Pharma
• Otsuka Pharmaceutical
• Daiichi Sankyo
• Eisai Co.
• Standard Chem and Pharma Co.
• Chunghwa Chemical and Pharmaceutical
• Yung Shin
• TWi Biotechnology
• OBI Pharmaceutical
• Daewoong Pharmaceutical
• Samsung Bioepis
• Celltrion

A company profile gives you the following information where available:
• Discussion of a company’s activities and outlook
• Company news relevant to the market

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect the East Asian Pharmaceutical industry?
Our new report discusses issues and events affecting the East Asian pharmaceutical market. You will find discussions, including qualitative analyses:
• Trends driving increased pharmaceutical demand
• Government programmes to reduce pharmaceutical spending

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

【レポートの目次】

1. Report Overview
1.1 East Asian Pharmaceutical Market Overview
1.2 East Asian Pharmaceutical Market Report Segmentation
1.3 Why You Should Read This Report?
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain
1.11 Exchange Rates

2. Introduction to the East Asian Pharmaceutical Market
2.1 National Market Definitions
2.1.1 Japan
2.1.2 Taiwan
2.1.3 Korea
2.2 Other Pharmaceutical Market Definitions
2.2.1 Originator Drugs
2.2.2 Generic Drugs (Generics)
2.2.3 OTC (Over-The-Counter)
2.2.4 Biosimilars
2.3 Introduction to the Global Pharmaceutical Market: A Brief Overview
2.4 Pharmaceutical Approval Regulations
2.4.1 Japan
2.4.2 Taiwan
2.4.3 Korea
2.5 The East Asian Pharmaceutical Market Forecast, 2016-2026

3. The Japanese Pharmaceutical Market
3.1 The Japanese Healthcare System
3.1.1 Costing and Healthcare Delivery
3.1.2 Increasing Generic Penetration: A Matter of Government Policy
3.1.3 Health Technology Assessments
3.2 The Japanese Pharmaceutical Market 2014 and 2015
3.2.1 The Japanese Pharmaceutical Market Forecast, 2016-2026
3.3 The Japanese Pharmaceutical Market 2016-2026: Submarket Shares
3.4 The Japanese Generic Drugs Market 2014
3.4.1 Public Perception Of Generics In Japan
3.4.2 The Japanese Generic Drugs Market Forecast, 2016-2026
3.5 The Japanese Originator Drugs Market 2014
3.5.1 The Japanese Originator Drugs Market Forecast, 2016-2026
3.6 The Japanese OTC Drugs Market 2014 and 2015
3.6.1 The Japanese OTC Drugs Market Forecast, 2016-2026
3.7 The Japanese Biosimilar Drugs Market 2014 and 2015
3.7.1 The Japanese Biosimilar Drugs Market Forecast, 2016-2026

4. Qualitative Analysis of the Japanese Pharmaceutical Market
4.1 SWOT Analysis of The Japanese Pharmaceutical Market, 2016-2026
4.1.1 Strengths
4.1.1.1 Affinity for Branded Products Helping Maintain Revenues
4.1.1.2 High Utilisation of Healthcare Facilities
4.1.1.3 Ageing Population Driving Demand
4.1.2 Weaknesses
4.1.2.1 Reduced Profit Margins Due to Government Pricing
4.1.2.2 Increasing Penetration of Generics Eroding Off-Patent Originator Revenues
4.1.2.3 Restrictions of the OTC Market and Low Consumer Desire
4.1.3 Opportunities
4.1.3.1 Ageing Population Resulting in Increased Demand For High-End Pharmaceuticals
4.1.3.2 New Regulation Allowing for Expansion of the Regenerative Medicine Sector – Sakigake Reforms
4.1.3.3 Increased Trade Opportunities via the Trans-Pacific Partnership (TPP)
4.1.4 Threats
4.1.4.1 Possible Funding Issues Due to Demographics
4.1.4.2 Expanded Use of Biosimilars May Erode Pharmaceutical Market Revenues
4.2 Porter’s Five Forces Analysis of the Japanese Pharmaceutical Market
4.2.1 Rivalry Among Competitors [Medium]
4.2.2 Threat of New Entrants [Medium]
4.2.3 Power of Buyers [Medium]
4.2.4 Power of Suppliers [Medium]
4.2.5 Threat of Substitutes [Medium]
4.3 Leading Japanese Domestic Pharmaceutical Companies
4.3.1 Takeda
4.3.1.1 Litigation Regarding ACTOS in the US
4.3.2 Astellas Pharma
4.3.3 Otsuka Pharmaceuticals
4.3.4 Daiichi Sankyo
4.3.5 Eisai Co.

5. The Taiwanese Pharmaceutical Market
5.1 The Taiwanese Healthcare System
5.1.1 Costing and Healthcare Delivery
5.1.2 Health Technology Assessments
5.2 The Taiwanese Pharmaceutical Market 2014 and 2015
5.2.1 The Taiwanese Pharmaceutical Market Forecast, 2016-2026
5.3 The Taiwanese Pharmaceutical Market 2016-2026: Submarket Shares
5.4 The Taiwanese Generic Drugs Market 2014 and 2015
5.4.1 The Taiwanese Generic Drugs Market Forecast, 2016-2026
5.5 The Taiwanese Originator Drugs Market 2014 and 2015
5.5.1 The Taiwanese Originator Drugs Market Forecast, 2016-2026
5.6 The Taiwanese OTC Drugs Market 2014 and 2015
5.6.1 The Taiwanese OTC Drugs Market Forecast, 2016-2026
5.7 The Taiwanese Biosimilar Drugs Market 2014 and 2015
5.7.1 The Taiwanese Biosimilar Drugs Market Forecast, 2016-2026

6. Qualitative Analysis of the Taiwanese Pharmaceutical Market
6.1 SWOT Analysis of The Japanese Pharmaceutical Market, 2016-2026
6.1.1 Strengths
6.1.1.1 Stable Levels of NHI Funding
6.1.1.2 High Trust and Utilisation of Healthcare Facilities
6.1.1.3 Increasingly Aged Population
6.1.2 Weaknesses
6.1.2.1 Strong Presence of Traditional Medicines
6.1.2.2 Political Isolation and Lack of Bilateral Trade Deals
6.1.3 Opportunities
6.1.3.1 Ageing Population and Associated Pharmaceutical Demand Set to Increase
6.1.3.2 Newly Elected Government Promises Support for Pharmaceutical and Biotechnology Industries
6.1.3.3 The Promotion of Taiwan as a Destination for Medical Tourism
6.1.4 Threats
6.1.4.1 The Influence of China on Taiwanese International Relations
6.1.4.2 Rapid Growth of Pharmaceutical Markets in Rival Asian Countries
6.2 Porter’s Five Forces Analysis of the Taiwanese Pharmaceutical Market
6.2.1 Rivalry Among Competitors [Medium]
6.2.2 Threat of New Entrants [Low]
6.2.3 Power of Buyers [High]
6.2.4 Power of Suppliers [Low]
6.2.5 Threat of Substitutes [High]
6.3 Leading Taiwanese Pharmaceutical Companies
6.3.1 Standard Chem and Pharma Co. (SCP)
6.3.2 Chunghwa Chemical and Pharmaceutical Co.
6.3.3 Yung Shin Pharmaceutical Industry
6.3.4 TWi Biotechnology
6.3.5 OBI Pharmaceutical

7. The Korean Pharmaceutical Market
7.1 The Korean Healthcare System
7.1.1 Costing and Healthcare Delivery
7.2 The Korean Pharmaceutical Market 2014 and 2015
7.2.1 The Korean Pharmaceutical Market Forecast, 2016-2026
7.3 The Korean Pharmaceutical Market 2016-2026: Submarket Shares
7.4 The Korean Generic Drugs Market 2014 and 2015
7.4.1 Pharmaceutical Price Controls and Measures Being Implemented In South Korea
7.4.2 KORUS FTA: The Free Trade Agreement Between South Korea And The US
7.4.3 The Free Trade Agreement between Korea And The European Union
7.4.4 The Korean Generic Drugs Market Forecast, 2016-2026
7.5 The Korean Originator Drugs Market 2014 and 2015
7.5.1 The Korean Originator Drugs Market Forecast, 2016-2026
7.6 The Korean OTC Drugs Market 2014 and 2015
7.6.1 The Korean OTC Drugs Market Forecast, 2016-2026
7.7 The Korean Biosimilar Drugs Market 2014 and 2015
7.7.1 The Korean Biosimilar Drugs Market Forecast, 2016-2026

8. Qualitative Analysis of the Taiwanese Pharmaceutical Market
8.1 SWOT Analysis of The Japanese Pharmaceutical Market, 2016-2026
8.1.1 Strengths
8.1.1.1 Increasing Strength of Domestic Companies
8.1.1.2 Most Rapidly Ageing Population in the World
8.1.1.3 High Rate of OTC Use Among Population
8.1.2 Weaknesses
8.1.2.1 Funding for Healthcare Becoming Stretched and Pharmaceutical Pricing Pressure
8.1.2.2 Export Prices Based on Domestic Reimbursement
8.1.3 Opportunities
8.1.3.1 Ageing Population Will Result in Increased Expenditure
8.1.3.2 Increasing Level of International Sales for Domestic Companies
8.1.3.3 Korea has Registered Interest in Joining the TPP
8.1.4 Threats
8.1.4.1 Korea is Highly Reliant on Other Countries for its Economic Growth
8.1.4.2 Continued Pricing Pressure
8.2 Porter’s Five Forces Analysis of the Korean Pharmaceutical Market
8.2.1 Rivalry Among Competitors [Medium]
8.2.2 Threat of New Entrants [Medium]
8.2.3 Power of Buyers [High]
8.2.4 Power of Suppliers [Low]
8.2.5 Threat of Substitutes [High]
8.3 Leading Korean Pharmaceutical Companies
8.3.1 Daewoong Pharmaceutical Co.
8.3.2 Samsung Bioepis
8.3.3 Celltrion

9. Interviews
9.1 Interview with Sawai Pharmaceuticals, Tokyo, Japan
9.1.1 State of the Pharmaceutical Market in Japan
9.1.2 Current Challenges Facing the Market
9.1.3 Area with Highest Potential for Growth
9.1.4 Effect of Government Policy
9.1.5 Effect of the TPP
9.1.6 Opinions on the Taiwanese and Korean Pharmaceutical Markets

10. Conclusions
10.1 The East Asian Pharmaceutical Market
10.1.1 Ageing Population and Increased Healthcare Spending Pressure
10.1.2 Slowing Economic Growth
10.2 The Japanese Pharmaceutical Market
10.3 The Taiwanese Pharmaceutical Market
10.4 The Korean Pharmaceutical Market

List of Tables
Table 1.1 Currency Exchange Rates, 2015
Table 2.1 Market Share (%) of the Global Pharmaceutical Market by Region, 2014
Table 2.2 The East Asian Pharmaceutical Market Forecast by Country: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 3.1 The Japanese Pharmaceutical Market Forecast by Submarket: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 3.2 The Japanese Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 3.3 The Japanese Originator Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 3.4 The Japanese OTC Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 3.5 The Japanese Biosimilar Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 4.1 SWOT Analysis of the Japanese Pharmaceutical Market, 2016-2026
Table 4.2 Takeda Pharmaceutical Company Overview
Table 4.3 Astellas Pharma Overview
Table 4.4 Otsuka Pharmaceuticals Overview
Table 4.5 Daiichi Sankyo Overview
Table 4.6 Eisai Co Overview
Table 5.1 The Taiwanese Pharmaceutical Market Forecast by Submarket: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 5.2 The Taiwanese Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 5.3 The Taiwanese Originator Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 5.4 The Taiwanese OTC Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 5.5 The Taiwanese Biosimilar Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 6.1 SWOT Analysis of the Taiwanese Pharmaceutical Market, 2016-2026
Table 6.2 Standard Chem and Pharma Co. Overview
Table 6.3 Chunghwa Chemical and Pharmaceutical Co. Overview
Table 6.4 Yung Shin Pharmaceutical Industry Overview
Table 6.5 TWi Biotechnology Overview
Table 6.6 OBI Pharmaceutical Overview
Table 7.1 The Korean Pharmaceutical Market Forecast by Submarket: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 7.2 The Korean Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 7.3 The Korean Originator Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 7.4 The Korean OTC Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 7.5 The Korean Biosimilar Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Table 8.1 SWOT Analysis of the Korean Pharmaceutical Market, 2016-2026
Table 8.2 Daewoong Pharmaceutical Co. Overview
Table 8.3 Samsung Bioepis Overview
Table 8.4 Celltrion Overview
Table 10.1 East Asian Pharmaceutical Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2026

List of Figures
Figure 1.1 Key Markets within the East Asian Pharmaceutical Market
Figure 2.1 Market Shares (%) of Pharmaceutical Market by Region, 2014
Figure 2.2 New Drug Regulatory Approval Pathway, Taiwan, 2016
Figure 3.1 The Japanese Pharmaceutical Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 3.2 The Japanese Pharmaceutical Market Submarkets by Revenue Share (%), 2014
Figure 3.3 The Japanese Pharmaceutical Market Submarkets by Revenue Share (%), 2020
Figure 3.4 The Japanese Pharmaceutical Market Submarkets by Revenue Share (%), 2026
Figure 3.5 The Japanese Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 3.6 The Japanese Originator Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 3.7 The Japanese OTC Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 3.8 The Japanese Biosimilar Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 4.1 A Comparison of the Updated and Previous Regulations Regarding Regenerative Medicine Testing in Japan
Figure 4.2 Porter’s Five Forces Analysis of the Japanese Pharmaceutical Market, 2016-2026
Figure 5.1 The Taiwanese Pharmaceutical Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 5.2 The Taiwanese Pharmaceutical Market Submarkets by Revenue Share (%), 2014
Figure 5.3 The Taiwanese Pharmaceutical Market Submarkets by Revenue Share (%), 2020
Figure 5.4 The Taiwanese Pharmaceutical Market Submarkets by Revenue Share (%), 2026
Figure 5.5 The Taiwanese Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 5.6 The Taiwanese Originator Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 5.7 The Taiwanese OTC Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 5.8 The Taiwanese Biosimilar Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 6.1 Porter’s Five Forces Analysis of the Taiwanese Pharmaceutical Market, 2016-2026
Figure 7.1 The Korean Pharmaceutical Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 7.2 The Korean Pharmaceutical Market Submarkets by Revenue Share (%), 2014
Figure 7.3 The Korean Pharmaceutical Market Submarkets by Revenue Share (%), 2020
Figure 7.4 The Korean Pharmaceutical Market Submarkets by Revenue Share (%), 2026
Figure 7.5 The Korean Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 7.6 The Korean Originator Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 7.7 The Korean OTC Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 7.8 The Korean Biosimilar Drugs Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 8.1 Porter’s Five Forces Analysis of the Korean Pharmaceutical Market, 2016-2026
Figure 10.1 East Asian Pharmaceutical Market Forecast: Revenue ($bn) and AGR (%), 2014-2026

【レポートのキーワード】

日本、台湾、韓国、アジア、製薬、医薬品

★調査レポート[東アジアの製薬市場:日本、台湾、韓国] ( East Asian Pharmaceutical Market 2016-2026 : Prospects for Growth Among Drug Classes in Japan, Taiwan and Korea / VGAIN6041531) 販売に関する免責事項
[東アジアの製薬市場:日本、台湾、韓国] ( East Asian Pharmaceutical Market 2016-2026 : Prospects for Growth Among Drug Classes in Japan, Taiwan and Korea / VGAIN6041531) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆